

ACG's Hepatitis School

For Physicians, Physician Assistants, Nurse Practitioners and Nurses



An Intensive Clinical Update on Hepatitis C Management

Friday, April 12, 2013 • 9:00 am - 4:15 pm

Washington Marriott at Metro Center Washington, DC

Course Co-Directors:

David E. Bernstein, MD, FACG Bruce A. Luxon, MD, PhD, FACG Zobair M. Younossi, MD, MPH, FACG





7:45 am Registration

8:55 am Introduction

9:00 am HCV Epidemiology and Cohort Screening Guidelines

Zobair M. Younossi, MD, MPH, FACG

Determine the prevalence of hepatitis C in the United States. Describe the natural history of HCV infection. Understand how to apply the current CDC screening recommendations in daily practice.

9:30 am A Guide to Pre-treatment Evaluation

James H. Lewis, MD, FACG

Describe the pre-treatment medical evaluation. Assess the impact of lifestyle issues on patient selection for HCV treatment. Define appropriate patient selection for HCV treatment. Be able to classify patients in treatment categories based upon previous treatment exposure.

10:00 am New Tests: Rapid Diagnostic Assays for HCV

Bruce A. Luxon, MD, PhD, FACG

Describe the current assays used in the evaluation and treatment of hepatitis C. Describe the current available point of care assays used for diagnosis of HCV.

10:30 am **Break**

10:45 am Clinical Challenges in HCV Management: Assessing Candidates for Therapy

David E. Bernstein, MD, FACG

Assess the impact of neuropsychiatric issues on initiation of HCV therapy. Describe the impact of co-morbid medical conditions on current HCV treatment. Describe the drug-drug interactions with protease inhibitor use. Describe the current recommendations for the treatment of patients with hepatitis C and cirrhosis.

11:15 am Current Treatments for HCV

Mitchell L. Shiffman, MD, FACG

Describe the current approved treatment regimens. Apply response guided therapies to the treatment of patients with hepatitis C. Describe the futility rules utilized with current HCV therapies. Describe the current recommended management of treatment experienced patients.

11:45 am Break and Boxed Lunch

12:00 noon LUNCHEON LECTURE: Management of Co-infection

Bruce A. Luxon, MD, PhD, FACG

Describe the challenges in treating patients with HIV/HCV co-infection. Describe the drug-drug interactions specific to patients with co-infection. Describe current approved therapies for HCV/HIV co-infection. Describe the use of HCV protease inhibitors in the treatment of patients with co-infection.

Program Description and Accreditation/CME

Hepatitis School is a day-long interactive educational program providing an immersion in hepatitis C management and a clinical update on new therapeutic modalities and approaches. The program will focus on the epidemiology of hepatitis C, the newly released cohort screening guidelines, the pre-treatment medical evaluation of the patient with hepatitis C, the currently approved therapies for hepatitis C and discuss the pipeline of new drug development for the treatment of hepatitis C. After completion of Hepatitis School, attendees will be able to identify appropriate candidates for therapy, describe the pre-treatment evaluation, recommend appropriate therapies for naïve and previously treated hepatitis C patients and be able to address the side effects of these therapies, and understand the timeline of new drug development for the treatment of hepatitis C infection.

The program is designed primarily for clinicians in GI/Hepatology as well as physician assistants, nurse practitioners and other advanced practice healthcare professionals interested in an aggressive but scientifically sound approach to the management of GI and liver illnesses.

The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American College of Gastroenterology designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

on Marriott at Metro Center • Washington, DC

12:30 pm **LUNCHEON LECTURE: Update on New Therapies and AASLD 2012**

David E. Bernstein, MD, FACG

Describe the new therapies being evaluated for the treatment of nongenotype 1 infection. Describe the

new interferon based combination therapies being assessed for the treatment of genotype 1 disease. Understand the potential for interferon-free regimens for the treatment of HCV. Understand the timeline of drug development in HCV.

1:00 pm **SEMINAR 1: Side Effect Management of Current Therapy**

Jorge L. Herrera, MD, FACG

Identify common side effects of current HCV therapy. Describe strategies to treat common side effects of hepatitis C therapies. Differentiate reversible and irreversible side effects of HCV treatments.

SEMINAR 2: Assessment Prior to Treatment - Do We Need 1:45 pm

IL28B Testing? Do We Need to Biopsy?

Mitchell L. Shiffman, MD, FACG

Describe the role of IL28B testing in the evaluation of HCV patients. Describe the various IL28B alleles. Describe the role of liver biopsy in the evaluation of HCV patients. Describe the effect of baseline

histology in determining treatment in HCV patients.

2:30 pm SEMINAR 3: HCV Management in the Community GI Setting -

How to Make it Work

Maly Tiev, NP Develop strategies to improve patient adherence to therapies.

Describe strategies for improved patient-provider communication. Describe strategies to overcome the challenges related to coverage

and reimbursement of HCV treatment.

3:15 pm **Interesting Case Presentations**

All Faculty

4:00 pm Wrap Up

4:15 pm **Adjourn**

Accommodations

The program will be held at the Washington Marriott at Metro Center in downtown Washington, DC. To make reservations, please call 1-888-236-2427 or 1-202-737-2200. Special meeting rates per night are \$199 plus tax (tax is currently 14.50%) for single or double. Additional fees of service charge and tax may apply. Reservations must be made by March 20, 2013. For more information on accommodations and reservations, please see the ACG Eastern Regional Course Brochure.

Registration

The registration fee includes a course syllabus on USB. All registrants must pay the full registration fee; partial registration is not available. Full refund of registration fees will be given, less a \$25 administrative fee, if written notice of cancellation is received by ACG by March 22, 2013. No refunds will be given after this date. Attendees may register by submitting the enclosed registration form with payment in U.S. funds to the College headquarters by fax to 301-263-9025, by mail to ACG, 6400 Goldsboro Road, Suite 200, Bethesda, MD 20817, or online at gi.org/educationand-meetings/regional-meetings.

More Information

For more information about this ACG meeting, call ACG at 301-263-9000. Americans with Disabilities Act: Attendees of this ACG Course who need additional reasonable accommodations or who have special needs (including dietary needs) should contact the ACG office at 301-263-9000 no later than March 22, 2013.



Registration Form

ACG's Hepatitis School

April 12, 2013, Washington, DC

Participant Information _ Please print or type information as you would like it to appear on your name badge. Name MUST circle all that apply: MD* D0* PhD RN NP I PN РΔ Pharm D Other:_ *Please enter your 10-digit NPI number above (required if physician) Address City State Zip Phone Fax Email Email required for meeting confirmation/receipt Payment Information*_ Hepatitis School Registration Fees - please check one \$75 ACG Member/Fellow * Full refund of registration fees will be given, less a \$25 \$75 ACG Trainee/GI Fellow/Resident Member administrative fee, if written \$75 ACG Allied Health Member notice of cancellation is received by ACG by March 22, \$75 ACG NP/PA Member 2013. No refunds will be \$100 Non-member Physician/PharmD/PhD/Guest given after this date. \$100 Non-member Trainee/GI Fellow/Resident Non-member NP/PA/Allied Health \$100 If attending both Hepatitis School & Eastern Regional Course** - please check one \$449 ACG Member/Fellow ** Attendees of the Eastern Regional Course must also \$160 ACG Trainee/GI Fellow/Resident Member designate breakout session \$275 ACG Allied Health Member and hands-on workshop choices using the Eastern \$275 ACG NP/PA Member Regional Course brochure, \$625 Non-member Physician/PharmD/PhD/Guest or you may register online at gi.org/education-and-\$254 Non-member Trainee/GI Fellow/Resident meetings/regional-meetings. \$425 Non-member NP/PA/Allied Health **Payment Type:** Check payable to ACG is enclosed (must be received before April 12, 2013) Credit Card: MASTERCARD VISA **AMEX** Cardholder Name Signature Card Number Exp. Date Security Code (3 or 4 digits) Today's Date

Return completed registration form with payment in U.S. funds to the ACG.

MAIL: ACG, 6400 Goldsboro Road, Suite 200, Bethesda, MD 20817 • FAX: 301-263-9025 ONLINE: gi.org/education-and-meetings/regional-meetings

Faculty

ACG's Hepatitis School • April 12, 2013 • Washington, DC

Course Co-Directors

DAVID E. BERNSTEIN, MD, FACG

Chief, Division of Hepatology and Center for Liver Diseases, North Shore Long Island Jewish Health Care System; Professor of Medicine, Hofstra North Shore-LIJ School of Medicine, New York, NY

BRUCE A. LUXON, MD, PhD, FACG

Professor of Medicine; Chair, Department of Medicine, Georgetown University Medical Center; Chief of Service, Department of Medicine, Georgetown University Hospital, Washington, DC

ZOBAIR M. YOUNOSSI, MD, MPH, FACG

Chairman, Department of Medicine, Inova Fairfax Hospital; Vice President for Research, Inova Health System; Professor of Medicine, Virginia Commonwealth University, Inova Campus, Falls Church, VA

Faculty

JORGE L. HERRERA, MD, FACG

Professor of Medicine, University of South Alabama, Mobile, AL

JAMES H. LEWIS, MD, FACG

Professor of Medicine, Georgetown University Medical Center, Washington, DC

MITCHELL L. SHIFFMAN, MD, FACG

Director, Liver Institute of Virginia, Richmond, VA

MALY TIEV, NP

North Shore-Long Island Jewish Health Care, New York, NY

